All News
Celecoxib Shines and Naproxen Tanks in the PRECISION Study
The PRECISION trial was published this week in the NEJM, presented at the Cardiology meetings in New Orleans, and presented today by Dr. Daniel Solomon at the 2016 ACR annual meeting in Washington, D.C. (citation source http://buff.ly/2fUmoqO)
Read Article
Diffuse Cutaneous Systemic Sclerosis: Results of the SCOT Trial
Diffuse cutaneous systemic sclerosis (dcSSc) is one of the most difficult autoimmune diseases to treat. In case of major organ involvement (lung, kidney), prognosis is poor and treatment options are limited.
Read Article
Guselkumab Efficacy and Tolerability in PsA/PsO
New treatment options for psoriatic arthritis continue to be explored at this year’s ACR/ARHP Annual Meeting in Washington, DC. Guselkumab (GUS) is a fully human monoclonal antibody against the p19 subunit of IL-23.
Read Article
Tocilizumab Infections Less in ACPA+ Patients
Tocilizumab is in the spotlight at this year’s ACR 2016 meeting but there is still much to learn, including more about its safety profile. In an abstract presented at today’s poster session (Abstract 2618), Morel, et al.
Read Article
ACR 2016 – Day 2 Highlights
Big highlights from Monday included the Hench Lecture, plenary session abstracts and presentations on drug safety and cost efficacy in rheumatoid arthritis.
Read Article
Maintenance of Remission in ANCA-vasculitis: MAINRITSAN study.
It is well known that ANCA-associated vasculitides can be hard to control and relapses are common. The choice of maintenance therapy is rather limited and therapies are not always effective.
Read Article
Herpes Zoster and Giant Cell Arteritis
The potential association of herpes zoster with giant cell arteritis (GCA) has been a debated topic and certainly has gotten some attention at ACR 2016 this year.
Read Article
MACRA: Not Just an Acronym Inside an Acronym
Education on MACRA is the key to successful survival. The important take home points noted in Dr. Will Harvey’s lecture at ACR 2016 (session title: Holy MACRA! How to Survive and Thrive in the New Era of MACRA, MIPS, and APMs) are stated below.
Read Article
ACR 2016 – Day 1 Highlights
The annual ACR meeting began last night with a number of famed rheumatologists being inducted as ACR Masters.
Read Article
CORRONA Presentations at ACR 2016
CORRONA, America's largest registry, has numerous presentations for this year's annual ACR/ARHP meeting. See below for the expanse of efficacy and safety issues covered by CORRONA investigators.
Read Article
Two New Biologics for Polyarticular JIA
On Monday, November 13, there were two new presentations at the annual ACR 2016 meeting on new biologics seeking approval for use in polyarticular juvenile arthritis.
Read Article
SPIRIT P1 Study - Ixekinumab Sustains Efficacy at 52 Weeks in Psoriatic Arthritis
Ixekinumab (IXE) is an IGG4 monoclonal antibody bindings with high affinity to IL -17A. Currently marketed at Taltz and approved for use in chronic plaque psoriasis, the agent is also being developed for use in psoriatic arthritis.
Read Article
Anti-IL-6 therapy shows promise in GCA
The opening day plenary session at ACR 2016 this morning featured John H.
Read Article
Termination of TCZ in GCA
Treatment of giant cell arteritis with tocilizumab is a hot topic at this year’s ACR meeting and, while GiACTA data was promising, a Swiss study reported less-favorable results at the poster session this morning (
Read Article
Unmet Needs: Prediction and early detection in SpA first-degree relatives
Why do diseases manifest in some family members but not in others? Antibodies can be found in patients who do not meet criteria for treatment, especially in first-degree relatives.
Read Article
RheumNow Week in Review – 11 November 2016
Dr Cush reviews highlights from this week on RheumNow.com
Read Article
The ACR 2016 Playbook
For me and many others, this is the Super Bowl of meetings. I haven’t missed an ACR meeting since I started going as a fellow in 1984. In this span of 30 years I have acquired insights on how to navigate such a big meeting. When I say big, I mean over 14,000 attendees from over 100 countries swarming throughout a convention center that has the elements of the Texas state fair, a gigantic Costco (on Saturday), and a sold-out concert.
Read Article
The Long Awaited PRECISION Study
The PRECISION study will be presented on Tuesday, November 15, 2016 by Dr. Elaine Husni from the Cleveland Clinic. This report brings to a climax the controversy ignited by the February 2005 3 day FDA Arthritis Advisory Committee review of the safety of the blockbuster COX-2 inhibitors, celecoxib, rofecoxib, and valdecoxib.
Read Article
Pfizer Features Xeljanz Presentations at ACR 2016
At this years 2016 ACR/ARHP Annual Meeting Pfizer will presen 20 abstracts, mostly centering around its JAK inhibitor tofacitinib (Xeljanz). They will also present the results of their Phase 3 OPAL studies of tofacitinib in patients with psoriatic arthritis.
Read Article
Lilly Features it's Rheumatoid and Psoriasis Biologics at ACR 2016
Eli Lilly & Co. has multiple presentations planned for the upcoming Annual meeting of the ACR/ARHP in Washington starting on Sunday, November 13th.
Read Article